DAFTAR PUSTAKA

1. WHO (2020). Health topics: Infectious diseases. World Health Organizations. www.who.int/topics/infectious_diseases/en/ . Diakses April 2020.

2. Centers for Disease Control and Prevention. National Center for Emerging and Zoonotic Infectious Disease. Atlanta: Centers for Disease Control and Prevention; 2012.

3. Hay SI, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abdallah F, et al. Global, Regional, and National Disability-Adjusted Life Years (DALYs) for 333 Disease and Injuries and Healthy Life Expectancy (HALE) for 195 Countries and Territories, 1990-2016: A Systemic Analysis for The Global Burden of Diseases Study 2016. The Lancet. 2017; 390 (10100): 1260-1344.

4. Nelwan EJ. The Threat of Emerging and Re-emerging Infections in Indonesia. *Acta medica Indonesiana*. 2019; 51(3):195-6.

5. Bereket W, Hemalatha K, Gatenet B, Wondossen T, Solomon A, Zeynudin A, et al. Update on Bacterial Nosocomial Infections. *Eur Rev Med Pharmacol Sci*. 2012; 16(8): 1039-44.

6. World Health Organization. Prevention of Hospital-Acquired Infections: a practical guide. Geneva: World Health Organization; 2002.

7. Kemenkes RI. Riset Kesehatan Dasar Tahun 2013. Jakarta: Kementrian Kesehatan RI; 2013.

8. Vallejo M, Cuesta D, Florez LE. Development of A Surgical Site Infection at a Tertiary Hospital in Colombia: A Clinical and Microbiological Profile. *Open Forum Infectious Disease*. 2019; 6(2): 450.

9. Centers for Disease Control and Prevention. Surgical Site Infection Event. Atlanta: Centers for Disease Control and Prevention; 2021.

10. Depkes RI. Profil Kesehatan Indonesia. Jakarta: Departemen Kesehatan RI; 2016.

11. Data Bakteri Hasil Pemeriksaan Spesimen Pus di Bagian Mikrobiologi RSUP Dr. M. Djamil Padang. Padang: RSUP Dr. M. Djamil; 2019.

12. World Health Organization. Global Guidelines for The Prevention of Surgical Site Infection. Geneva: World Health Organization; 2016.

13. Sulistyaningrum NF. Pola Kuman dan Uji Senstivitasnya Terhadap Antibiotik Pada Penderita Infeksi Luka Operasi di RSUD Dr Moewardi

Periode Januari-Juli 2015(Skripsi). Surakarta: Universitas Muhammadiyah Surakarta; 2016.

14. Wardoyo EH, Tjoa E, Ocvyanty D, Moehario LH. Infeksi Luka Operasi (ILO) di Bangsal Kebidanan dan Kandungan RSUPN Cipto Mangunkusumo (RSCM): Laporan Serial Kasus Bulan Agustus-Oktober 2011. *Jurnal Cermin Dunia Kedokteran*. 2014; 5(41): 332-35.

15. Barung S, Sapan HB, Sumanti WM, dan Tubagus R. Pola Kuman dari Pasien Infeksi Luka Operasi pada Pasien Multitrauma. *Jurnal Biomedik*. 2017. 9(2): 115-20.

16. Sommeng F, Sodiqah Y, Diennilla FR. Identifikasi Bakteri Udara di Ruang Operasi dengan Bakteri pada Luka Infeksi Pasien Pasca Operasi di Rumah Sakit Ibnu Sina. *UMI Medical Journal*. 2019; 4(1): 37-51.

17. Bayot ML, Bragg BN. Antimicrobial Susceptibility Testing. In: Stat Pearls. Treasure Island: Stat Pearls Publishing. 2021.https://www.ncbi.nlm.nih.gov/books/NBK539714/ . Diakses Oktober 2021.

18. Belkum A, Bachmann TT, Ludke Gerd, Lisby JG, Kahlmeter G, et al. Developmental Roadmap for Antimicrobial Susceptibility Testing System. *Nat Rev Microbiol*. 2019; 17: 51.62.

19. Ierano C, Nankervis JM, James R, Rajkhowa A, Peel T, Thursky K, et al. Surgical Antimicrobial Prophylaxis. *Aust Prescr*. 2017; 40(6): 225-9.

20. World Health Organizations. Antibiotics of Choice for Surgical Antibiotic Prophylaxis. Geneva: World Health Organizations; 2010.

21. Asia Pacific Society of Infection Control. Pedoman APSIC untuk Pencegahan Infeksi Daerah Operasi. Asia Pacific Society of Infection Control; 2018.

22. Goodman, Gilman. Manual of Pharmacology and Therapeutics. New York: The Mc Graw Hill; 2008.

23. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. *American Journal of Health-System Pharmacy*. 2013; 70(3): 195-283.

24. Syachroni. Antibiotic Prophylaxis Compliance for Clean-Contaminated Wounds in A District Hospital Jakarta. *Health Science Journal of Indonesia*. 2015; 6(1): 57-62.

25. Desiyana LS, Soemardi A, Radji M. Evaluasi Penggunaan Antibiotika Profilaksis di Ruang Bedah Rumah Sakit Kanker Dharmais Jakarta dan

Hubungannya dengan Kejadian Infeksi Daerah Operasi. *Indonesian Journal of Cancer*. 2008; 2(4): 126-31.

26. Nuraliyah, Hapsari I, Utaminingrum W. Evaluasi Penggunaan Antibiotika Profilaksis pada Pasien Seksio Sesarea di Rumah Sakit Bersalin Panti Nugroho Purbalingga Tahun 2009. *Pharmacy*. 2012; 9(2): 31-9.

27. Nurfitri R. Evaluasi Penggunaan Antibiotik Profilaksis pada Pasien Bedah Sesar (*Sectio Caesarea*) di RSUP Dr. M. Djamil Padang (Skripsi). Padang : Universitas Andalas; 2020.

28. Pertiwi N. Evaluasi Penggunaan Antibiotik Profilaksis padaPasien Bedah Ortopedi dengan Fraktur Femur di RSUP Dr. M. Djamil Padang (Skripsi). Padang : Universitas Andalas; 2020.

29. Centers for Disease Control and Prevention. Procedure-Associated Module: Surgical Site Infection (SSI) Event. Centers for Disease Control and Prevention; 2020.

30. Sjamsuhidajat R, Karnadihardja W, Prasetyono TO, Rudiman R, editors. Buku Ajar Ilmu Bedah Sjamsuhidajat-De Jong. Jakarta: Penerbit EGC; 2010.

31. Bui T, Preuss CV. Cephalosporins. In: Stat Pearls . Treasure Island : Stat Pearls Publishing. 2021. https://www.ncbi.nlm.nih.gov/books/NBK551517/ . Diakses September 2021.

32. Shahbaz K. Cephalosporins: Pharmacology and Chemistry. *Pharmaceutcal and Biological Evaluations*. 2017; 4(6): 234-8.

33. National Center for Biotechnology Information (2020). Pubchem Compound:Cefazolin.https://pubchem.ncbi.nlm.nih.gov/compound/Cefazolin . Diakses September 2020.

34. Kusaba T. Safety and Efficacy of Cefazolin Sodium in The Management of Bacterial Infection and in Surgical Prophylaxis. *Clinical Medicine. Therapeutic*. 2009; 1: CMT S2096.

35. Tribuddharat S, Sathitkarnmanee T, Kitkhuandee A, Theerapongpakdee S, Ngamsaengsirisup K, Chanthawong, S. A Fatal Adverse Effect of Cefazolin Administration: Severe Brain Edema in A Patient with Multiple Meningiomas. *Drug, Healthcare and Patient Safety*. 2016; 8: 9-12 .

36. Macy E, Contreras R. Adverse Reactions Associated with Oral aand Parenteral Use of Cephalosporins: A Retrospective Population-Based Analysis. *J Allergy Clin Immunol.* 2015;135(3):745-52.

37. Medidata. MIMS Petunjuk Konsultasi Edisi 17. Jakarta: Buana Ilmu Populer; 2017.

38. Rx List The Internet Drug Index (2020). Cefazolin. https://www.rxlist.com/cefazolin-drug.htm . Diakses November 2020.

39. National Center for Biotechnology Information (2020). Pubchem Compound:Ceftriaxone.https://pubchem.ncbi.nlm.nih.gov/compound/Ceftriaxone . Diakses September 2020.

40. Rawls SM. Antibiotics, β-Lactam. In: Michael JA, Robert BD, editors. Encyclopediaof The Neurological Sciences. 2nd Ed. Temple University of School Medicine Philadelphia: Academic Press; 2014. 207-9

41. DailyMed(2020). Label: Ceftriaxone – ceftriaxone sodium injection, powder, for solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid= 4d1ad77f-2c6b-4250-82e5-ab3574444e08 . Diakses September 2020.

42. Anjalimol PT, Mary JP, Achenkunju V, Menaka K, Sherief SH, Sivakumar T. A Case Report on Ceftriaxone Induced Hypersensitivity Reaction. *International Journal of Research and Review*. 2019; 6(11): 533-4.

43. Rx List The Internet Drug Index (2020). Ceftriaxon. https://www.rxlist.com/ceftriaxone-drug.htm . Diakses November 2020.

44. Pacifici GM, Marchini G. Clinical Pharmacology of Cefotaxime in Neonates and Infants: Effects and Pharmacokinetics. *Int J Pediatr*. 2017; 5(11): 6111-38.

45. National Center for Biotechnology Information (2021). Pubchem Compound: Cefotaxime. https://pubchem.ncbi.nlm.nih.gov/compound/Cefotaxime. Diakses Januari 2021.

46. AFT Pharmaceuticals Ltd. Cefotaxime data sheet Maret 2016. https://www.medsafe.govt.nz/profs/Datasheet/c/Cefotaximeinjaft.pdf. Diakses Januari 2021.

47. Padda IS, Nagalli S. Cefotaxime. Treasure Island: StatPearls Publishing 2020. https://www.ncbi.nlm.nih.gov/books/NBK560653/ . Diakses Januari 2021.

48. Adelberg, Jawetz E, Melnick JE, editors. Mikrobiologi Kedokteran . Jakarta: EGC; 2012

49. Karsinah, Lucky HM, Suharto, Mardiastuti HW. Batang Negatif Gram. In: Syahrurrachman A, et al., editors. Buku Ajar Mikrobiologi Kedokteran. Edisi Revisi. Jakarta: Binarupa Aksara.p.185-228.

50. Integrated Taxonomic Information System (2020). *Escherichia coli*. Integrated Taxonomic Information System. https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=285#null. Diakses November 2020.

51. Donnenberg MS, Whittam TS. Pathogenesis and Evolution of Virulence in Enteroptahogenic and Enterohemorraghic *Escherichia coli*. *J Clin Invest*. 2001; 107(5): 539-548.

52. Lai Y, Rosenshine I, Leong JM, Frankel G. Intimate Host Attachement: Enteropathogenic and Enterohaemorraghic *Escherichia coli*. *Cellular Microbiology*. 2013; 15: 1796-808.

53. Isidean SD, Riddle MS, Savarino SJ, Porter CK. A Systemic Review of ETEC Epidemiology Focusing on Colonization Factor and Toxin Expression. *Vaccine*. 2011; 29: 6167-78.

54. Antimicrobe (2020). *Escherichia coli*: Pathogenesis and Clinical Infections. http://antimicrobe.org/b104.asp#top . Diakses November 2020.

55. Warsa UC. Kokus Positif Gram. In: Syahrurrachman A, et al., editors. Buku Ajar Mikrobiologi Kedokteran. Edisi Revisi. Jakarta: Binarupa Aksara.p. 125-134.

56. Integrated Taxonomic Information System (2020). Staphylococcus aureus. Integrated Taxonomic Information System.https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=369#null. Diakses Juli 2020.

57. Otto M. *Staphylococcus aureus* Toxins. *Curr Opin Microbiol*. 2014; 17: 32-7.

58. Kobayashi SD, Malachowa N, DeLeo FR. Pathogenesis of *Staphylococcus aureus* Abcesses. *Am J Pathol*. 2015; 185(6): 1518-27.

59. DeLeo FR, Diep BA, Otto M. Host Defense and Pathogenesis in *Staphylococcus aureus* Infections. *Infect Dis Clin Am*. 2009; 6: 17-34.

60. Integrated Taxonomic Information System (2021). *Staphylococcus epidermidis*. Integrated Taxonomic Information System. https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=377#null . Diakses Januari 2021.

61. Microbe Notes (2020). Staphylococcus epidermidis-An Overview. Microbe Notes. https://microbenotes.com/staphylococcus-epidermidis/ . Diakses Januari 2021.

62. Bresco MS, Harris LG, Thompson K, Stanic B, Morgenstern M, Omahony L, et al. Pathogenic Mechanisms and Host Interactions in *Staphylococcus epidermidis* Device-Related Infection. *Front Micribiol*. Agustus 2017; 8: 1-24.

63. Nuryastuti T. *Staphylococcus epidermidis*: How to Turn from comensal to be A Pathogen Lifestyle. *J Med Sci*. Januari 2018; 50(1): 113-27.

64. Li B, Zhao Y, Liu C, Chen Z, Zhou D. Molecular Pathogenesis of *Klebsiella pneumoniae*. *Future Microbiol*. 2014; 9(9): 1071-81.

65. Integrated Taxonomic Information System (2020). *Klebsiella pneumoniae*. Integrated Taxonomic Information System. https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=9751#null. Diakses November 2020.

66. Paczosa MK, Mecsas J. Klebsiella pneumoniae: Going on The Offense with a Strong Defense. *Microbiology and Molecular Biology Reviews.* 2016; 80(3):629-61.

67. Clegg S, Murphy CN. Epidemiology and Virulence of *Klebsiella pneumoniae. Microbiology Spectrum*. 2016; 4(1): 435-57.

68. Wahyuni NA. Uji Aktivitas Antibakteri Ekstrak Bunga Cengkeh terhadap *Klebsiella penumoniae* Secara *In vitro*(Skripsi). Malang: Universitas Islam Negeri Maulana Malik Ibrahim; 2020.

69. Tarina NTI, Kusuma SAF. Deteksi Bakteri *Klebsiella penumoniae*. *Farmaka*. 2017; 15(2): 119.

70. Valentini M, Gonzalez D, Mavridou DA, Filloux A. Lifestyle Trasitions and Adaptive Pathogenesis of *Pseudomonas aeruginosa*. *Current Opinion in Microbiology*. 2018; 41: 15-20.

71. Integrated Taxonomic Information System (2020). *Pseudomonas aeruginosa*. Integrated Taxonomic Information System. https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=965278#null . Diakses November 2020.

72. Azam MW, Khan AU. Updates on The Pathogenicity Status of *Pseudomonas aeruginosa*. *Drug discovery today*. 2019; 24(1): 350-9.

73. Alhazmi A. *Pseudomonas aeruginosa* – Pathogenesis and Pathogenic Mechanisms. *International Journal of Biology*. 2015; 7(2): 1-24.

74. Integrated Taxonomic Information System (2021). *Proteus mirabilis*. Integrated Taxonomic Information System. https://www.itis.gov/

servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=965102#null . Diakses Januari 2021.

75. Wang Y, Pan Xiaoling. Bacteria: *Proteus*. *Encyclopedia of Food Safety*. 2014: 486-89.

76. Zafar U, Taj MK, Nawaz I, Hussain A, Taj I, Abideen Z, et al. *Proteus mirabilis* as a Pathogenic Organism. *Int J Biosci*. 2019; 14(3): 443-50.

77. Soleha TU. Uji Kepekaan terhadap Antibiotik. Jurnal Kedokteran Universitas Lampung. 2015; 5(9): 119-23.

78. Lalita MK. Manual on Antimicrobial Susceptibility Testing. Performance Standards for Antimicrobial Testing. 2012.

79. Departemen Kesehatan Republik Indonesia. Klasifikasi Umur Menurut Kategori. Jakarta: Ditjen Yankes; 2009.

80. Azis SI, Ompusunggu PMT, Irawiraman H. Gambaran Kejadian Infeksi Luka Operasi (ILO) Pasca Bedah Abdomen di RSUD Abdul Wahab Sjahranie Samarinda. *Jurnal Kebidanan Mutiara Mahakam*. 2020; 8(1): 21-37.

81. Laloto TL, Gemeda DH, Abdella SH. Incidence and Predictors of Surgical Site Infection in Ethiopia. *BMC Infectious Disease*. 2017; 17(119): 1-9.

82. Sutariya PK, Chavada MV. Incidence and Determinants of The Surgical Site Infection: A Hospital Based Longitudinal Study. *Int Surg J*. 2016; 3(4): 2202-6.

83. Kaye KS, Schmit K, Pieper C, Sloane R, Caughlan KF, Sexton DJ, et al. The Effect of Increasing Age on The Risk of Surgical Site Infection. *Journal of Infectious Disease*. 2005; 191: 1056-62.

84. Ghali H, Rejeb MB, Chahed C, Harrabi F, Rejeb OB, Fredj SB, et al. Incidence and Risk Factors of Surgical Site Infection in General Surgery Departemen of A Tunisian Tertiary Teaching Hospital. *Canadian Journal of Infection Control*. 2018; 33(1): 25-32.

85. Cheng K, Li J, Kong Q, Wang C, Ye N, Xia G. Risk Factors for Surgical Site Infection in a Teaching Hospital. *Patient Preference and Adherence*. 2015; 9: 1171-7

86. Asrawal, Summary R, Hasan D, Daniel D. Faktor Risiko Terjadinya Infeksi Daerah Operasi pada Pasien Bedah Orthopedi di RSUP Fatmawati Periode Juli-Oktober 2018. *J Sains Farm Klin*. 2019; 6(2): 104-12.

87. Aghdassi SJS, Schroder C, Gastmeier P. Gender-Related Risk Factors for Surgical Site Infections. *Antimicrobial Resistance and Infection Control*. 2019; 8(95): 1-8.

88. Isik O, Kaya E, Dundar HZ, Sarkut P. Surgical Site Infection: Re-Assessment of The Risk Factors. *Chirurgia*. 2015; 110(5): 457-61.

89. Wiguna DS. Pola Resistensi Bakteri terhadap Antibiotik pada Penderita Infeksi Luka Operasi (ILO) di Rumah Sakit X (Skripsi). Surakarta: Universitas Muhammadiyah Surakarta; 2016.

90. Gormeli G, Karakaplan M, Korkrnaz MF, Tekerekoglu MS, Selcuk EB, et al. Orthopedic Surgical Wound Infection: Microorganisms and Resistance Figures. *J Turgut Ozal Med Cent*. 2015; 22(1): 13-7.

91. Komite Pengendalian Resistensi Antimikroba (PPRA) RSUP Dr. M. Djamil Padang. Laporan Pola Kuman RSUP Dr. M. Djamil Padang Periode 2019-2020.

92. Sane RM, Shahani SR, dan Kalyanshetti AA. Antibiotic Prescription Pattern in Surgical Wards of MGM Hospital, Kamothe. *Int J Infect*. 2018; 5(1): 1-6.

93. Moges G, Belete L, Mengensha Y, dan Ahmed S. Evaluation of Surgical Antimicrobial Prophylaxis and Incidence of Surgical Site Infection at Borumeda Hospital, Northeast Ethiopia. *Drug, Healthcare and Patient Safety*. 2020; 12: 257-68.

94. Aprilia Y, Nurmainah, Fajriaty I. Gambaran Penggunaan Antibiotik Profilaksis pada Pasien Bedah Tulang Fraktur Terbuka Ekstrimitas Bawah di RSUD Dokter Soedarso Pontianak. *Jurnal Mahasiswa Farmasi Fakultas Kedokteran UNTAN*. 2017; 4(1): 1-9.

95. Sofyan O dan Setiawati N. Evaluasi Penggunaan Antibiotik Profilaksis yang Rasional pada Pasien Bedah di Rumah Sakit Khusus Bedah Adelia. *Jurnal Kefarmasian Akfarindo*. 2019; 4(2): 36-41.

96. Departemen Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 2406/MENKES/PER/XII/2011 Tentang Panduan Umum Penggunaan Antibiotik. 2011: 1-69.